万拉法辛缓释剂与帕罗西汀治疗广泛性焦虑障碍的对照研究

目的研究万拉法辛缓释剂与帕罗西汀治疗广泛性焦虑障碍的疗效与安全性。方法根据DSM-IV诊断标准将广泛性焦虑障碍患者随机分成2组,万拉法辛缓释剂治疗组（25例）和帕罗西汀治疗组（23例）,均治疗8周;采用HAMA、CGI-SI评定疗效;采用TESS、实验室检查及体查评价安全性。结果HAMA、CGI-SI量表分在治疗过程中显著下降,2组疗效相当,均未有严重不良事件发生。结论万拉法辛缓释剂与帕罗西汀是安全有效的治疗广泛性焦虑障碍的药物,患者对药物的耐受性及依从性好。

Controlled study of generalized anxiety disorder with venlafaxine extended release and paroxetine

Objective To evaluate the efficacy and tolerability of venlafaxine extended release（XR） and paroxetine for patients with generalized anxiety disorder（GAD）.Methods Twenty-five patients who met DSM-IV criteria for GAD were randomly assigned to venlafaxine XR and another 23 patients to paroxetine and the treatment lasted 8 weeks.Efficacy was assessed with the Hamilton Rating Scale for Anxiety（HAMA） and Clinical Global Impression of Illness（CGI-SI） scale.Safety was evaluated by TESS,laboratory and physical examination throughout the study.Results The scores showed a significant decrease over time in both groups.Effects of both groups were similar.There were no serious adverse events in both groups.Conclusion Either venlafaxine XR or paroxetine would be effective and tolerable for patients with GAD.